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SUMMARY
Aims: The aim of this study was to quantify diagnostic inertia (DI) when the
physician fails to diagnose hypertension and determine its associated factors.
Methods: This cross-sectional, observational study involved all patients without a
diagnosis of hypertension who had their blood pressure (BP) measured at least
three times during the second half of 2010 (N = 48,605). Patients with altered
mean BP figures (≥ 140/90 mmHg) were considered to experience DI. Secondary
variables: gender, atrial fibrillation, diabetes mellitus, dyslipidemia, cardiovascular
disease, age and the physician having attended a cardiovascular training course
(ESCARVAL). Associated factors were assessed by multivariate logistic regression
analysis. Results: Diagnostic inertia was present in 6450 patients (13.3%, 95%
CI: 13.0–13.6%). Factors significantly associated with DI were: male gender
(OR = 1.46, 95% CI: 1.37–1.55, p < 0.001), atrial fibrillation (OR = 0.73, 95%
CI: 0.58–0.92, p = 0.007), the ESCARVAL cardiovascular course (OR = 0.88,
95% CI: 0.81–0.96, p = 0.005), diabetes mellitus (OR = 0.93, 95% CI: 0.87–
0.99, p = 0.016), cardiovascular disease (OR = 0.77, 95% CI: 0.67–0.88,
p < 0.001) and older age (years) (18–44?OR = 1; 45–59?OR = 12.45, 95%
CI: 11.11–13.94; 60–74?OR = 18.11, 95% CI: 16.30–20.12; ≥ 75?
OR = 20.43, 95% CI: 18.34–22.75; p < 0.001). The multivariate model had an
area under the ROC curve of 0.81 (95% CI: 0.80–0.81, p < 0.001). Conclu-
sions: This study will help clinical researchers differentiate between the two forms
of DI (interpretation of a positive screening test and interpretation of positive
diagnostic criteria). The results found here in patients with hypertension suggest
that this problem is prevalent, and that a set of associated factors can explain
the outcome well (AUC>0.80).
What’s known
The concept of diagnostic inertia, developed in 2010,
was considered to be failure in the interpretation of a
positive screening test. Four years later the concept
was studied in dyslipidemia, with diagnostic inertia
being assessed when making a diagnostic
confirmation. The prevalence of diagnostic inertia
was seen to be very high.
What’s new
We have now examined the concept of diagnostic
inertia with the results of more than just one
measurement (not a screening test) in patients with
hypertension. The proportion of inertia was much
lower than that for a screening test. We report
certain associated factors that may help understand
the possible causes of this inertia.
Introduction
In 2001, Phillips introduced the concept of clinical
inertia, defining it as failure by the physician to initi-
ate or intensify treatment when this action was indi-
cated (1). This inertia, coupled with poor medication
adherence by the patient, is considered the main
cause of poor control of chronic diseases such as
hypertension (2).
In 2010, Gil-Guillen et al. examined the idea of
clinical inertia, developing the concept of diagnostic
inertia (DI), defined as the conservative attitude of
physicians when interpreting a positive screening test.
In other words, when a patient with a positive screen-
ing test but without a diagnosis of a specific disease is
labelled as ‘not sick’ by the physician (3,4).
Resulting from this derivation of the classical
concept by Phillips (1,3,4), several studies have anal-
ysed the attitude of physicians when interpreting
altered results of a screening test for cardiovascular
risk factors (hypertension, diabetes mellitus and dys-
lipidemia) (5–7). In 2014, Palazon-Bru et al. pro-
posed a derivation of the original concept of DI,
classifying as inertia the lack of diagnostic confirma-
tion although the physician has two or more lipid
profile measurements for a patient without a diag-
nosis of dyslipidemia (8). Furthermore, this study
undertook a review detailing the main characteristics
of studies that had assessed this problem but did
not include the concept of DI, both in altered
screening results and when two or more lipid pro-
file results were available. The prevalence of this
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problem was shown to be very high in some geo-
graphical regions (8–11).
Considering that the concept of DI in the presence
of more than one measurement (not a screening test)
has only been evaluated in dyslipidemia (8), it is
important to analyse this concept in other chronic
diseases, such as hypertension. Accordingly, to better
understand DI, we conducted a study assessing its
prevalence and associated factors in hypertension.
With the findings, we can take measures aimed at
physicians to prevent DI and thus improve the detec-
tion and treatment of high blood pressure and con-
sequently reduce the incidence of cardiovascular
disease.
Materials & methods
Study population
The study population comprised patients without
hypertension in the Valencian Community (a
Mediterranean region on the east coast of Spain),
with a minimum of three visits to the health centre
with blood pressure (BP) measurements taken at
each visit [the number necessary to confirm the diag-
nosis (12,13)]. This community has approximately 5
million inhabitants and the health system is free and
universal. Furthermore, this region has an electronic
database for the health system that includes all levels
of care, and all drugs have to be prescribed through
this system (8,14).
Study design and participants
This cross-sectional, observational study analysed a
sample of patients treated by their primary care
physician at their health centre in the Valencian
Community during the second half (July to Decem-
ber) of 2010. These patients had to have no diagnosis
of hypertension, as seen from the electronic medical
record (ICD-9-CM code 401.x or having a prescrip-
tion for antihypertensive medication). They were also
required to have a record of BP readings taken on at
least three visits to the health centre, thus enabling
the primary care physician to confirm or rule out
the diagnosis of hypertension in accordance with the
European guidelines on hypertension management
(12,13).
The medical records database was consulted to
obtain the patient sample, selecting those patients
who met the inclusion criteria.
Variables and measurements
The primary variable was DI, defined as having mean
BP values above normal (BP ≥ 140/90 mmHg)
(12,13). In other words, if a patient had abnormal
readings and was undiagnosed, this implied failure
by the primary care physician to diagnose the patient
with hypertension. Note that the cut-off point of
130/80 mmHg was not used for diabetic patients or
those patients who had cardiovascular disease
because it is the goal of the treatment, i.e. after they
have been diagnosed with hypertension, and our
patients had not been diagnosed with this condition
(see Study Design and Participants).
Secondary variables were: gender, atrial fibrillation,
diabetes mellitus, dyslipidemia, cardiovascular disease
(12), age (18–44, 45–59, 60–74 and ≥ 75 years) and
ESCARVAL training. The diagnoses were obtained
from the electronic medical records using the
ICD-9-CM codes for each disease. In addition, for
dyslipidemia and diabetes, the drugs prescribed by
the primary care physician (lipid-lowering drugs,
insulin and oral antidiabetic agents) were reviewed.
Gender and age were also obtained from the elec-
tronic medical records. The ESCARVAL study docu-
ments all the health professionals who have
completed the training course, including updates on
cardiovascular disease, both for clinical practice and
for research (15). Age was categorised following the
structure proposed by Palazon-Bru et al. in their
study on dyslipidemia (8). In addition, the patients
who experienced inertia were then categorised in
two groups: those with BP values ≥ 160/100 and the
rest (12,13). Finally, we determined how many
patients with diabetes or cardiovascular disease with
BP values ≥ 130/80 mmHg had BP values ≥ 140/
90 mmHg, because it is important to know how
many patients with a target of 130/80 mmHg actu-
ally had BP values below 140/90 mmHg, perhaps
suggesting a lack of knowledge of the guidelines
(12,13).
Sample size
As the sample was extracted from the medical
records database, no prior sample size was obtained
for consideration in our study. Consequently, we cal-
culated the precision of the sample to estimate a pro-
portion (DI). The sample comprised a total of
48,605 patients. To estimate the prevalence, assuming
a type I error of 5% and a maximum expected pro-
portion, a precision of 0.44% was obtained.
Statistical methods
Since all our variables were qualitative, the descrip-
tive analysis was performed using frequencies and
percentages. Associated factors were identified
through the construction of a logistic regression
model in which DI was the dependent variable and
all the secondary variables were the independent
variables. The adjusted odds ratios (ORs) were then
obtained for each of the factors analysed. The
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goodness-of-fit of the model was assessed using the
likelihood ratio test and by calculating the area under
the ROC curve. Finally, we determined the differ-
ences in the patients who experienced inertia
between those with BP values ≥ 160/100 mmHg and
the rest using the chi-squared test. The significance
level was set at 5% and for each relevant parameter;
its associated confidence interval was calculated. The
statistical software used was IBM SPSS Statistics 19.
Ethical issues
The study was approved by the Public Health Ethics
Committee of the Valencian Community. This com-
mittee allowed analysis of the data from the medical
records in an anonymised and encrypted fashion.
Access to information was completely restricted,
ensuring that the extracted data could not be made
public. No consent was sought from the patients
included in the study because by obtaining the data
in a completely anonymous manner, it was impossi-
ble to contact the patients. The Committee approved
this procedure. A more detailed description of this
entire process can be seen in the study by Palazon-
Bru et al. (8).
Results
A total of 48,605 patients without hypertension and
with a sufficient number of BP readings to make
this diagnosis attended their health centre in the
Valencian Community in the second half of 2010.
Of this number, 6450 patients presented DI (13.3%,
95% CI: 13.0–13.6%), of whom 468 (7.2%; 95% CI:
6.6–7.9%) had BP values ≥ 160/100 mmHg. More-
over, among patients with BP values ≥ 130/
80 mmHg and with cardiovascular disease or dia-
betes (n = 5781), a total of 2400 patients had BP
readings above 140/90 mmHg (41.5%, 95% CI:
40.2–42.8%).
Table 1 shows the descriptive characteristics of the
sample. There were fewer men (22.9%), a high
prevalence of cardiovascular risk factors (diabetes,
18.4%; dyslipidemia, 24.8%) and 2.7% of the
patients had cardiovascular disease. Most of the
patients ranged in age between 18 and 44 years
(55.7%).
Analysis of the factors associated with DI obtained
through the multivariate model produced the follow-
ing profile: male gender (OR = 1.46, p < 0.001), not
being diagnosed with atrial fibrillation (OR = 0.73,
p = 0.007), having a health professional who had not
taken the ESCARVAL training course (OR = 0.88,
p = 0.005), not having a diagnosis of diabetes
(OR = 0.93, p = 0.016) or cardiovascular disease
(OR = 0.77, p < 0.001), and older age (p < 0.001).
The model was highly significant (p < 0.001) and
exhibited an area under the ROC curve of 0.81 (95%
CI: 0.80–0.81, p < 0.001; Figure 1).
Analysis of the differences in patients experiencing
DI (Table 2) showed that patients with higher BP
readings (≥ 160/100 mmHg) had a significantly
(p < 0.05) lower prevalence of dyslipidemia (36.6%
vs. 44.2%, p < 0.001) and were older (p = 0.014).
The remaining variables showed no significant differ-
ences between the two DI groups.
Discussion
Summary
By having been carried out in a different disease, in
this case hypertension, this study reinforces the con-
cept of DI developed by Palazon-Bru et al. con-
ducted in dyslipidemia (8). The proportion of DI in
our study was 13.3%, indicating that primary care
physicians did not diagnose hypertension in approx-
imately one in seven patients who met the criteria
for this condition. Factors associated with DI were
also identified. Furthermore, among patients experi-
encing DI, one in 14 had BP values above 160/
100 mmHg. Indeed, differences were found between
those with BP values above 160/100 mmHg and the
rest.
Strengths and limitations
The main strength of this work is that it reinforces
the concept of DI using two or more determina-
tions of the relevant control parameter (depending
on the disease) (8), evaluating DI in a novel way in
hypertension. Moreover, the use of an information
source encompassing all levels of medical care, in a
region of nearly five million inhabitants, minimised
any potential information bias. In addition, the area
under the ROC curve of the multivariate model
was greater than 80%, indicating that, although we
did not analyse the number of medications a
patient was already taking, the number of chronic
conditions (comorbidities) already diagnosed, the
presence of chronic kidney disease, or socioeco-
nomic status the factors found were strongly related
to DI. Finally, the error in estimating the propor-
tion of inertia was less than 1%, which is very sat-
isfactory.
Regarding limitations, since we only included
patients attending their health centre during a speci-
fic period of time, there may have been selection
bias. In addition, we only included patients who had
a record of BP readings, i.e. those for whom the
healthcare professional had recorded these values in
the electronic medical record. Given that we cannot
minimise this bias, it would be interesting to repeat
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this study in the general population and with pri-
mary data sources with manually recorded BP values.
Another possibility might be to synchronise the BP
measuring devices with the electronic medical record
to automatically record the measurement. In our
region, this procedure is already in use for lipid mea-
surements.
Comparison with the existing literature
When we compare our results with those of other
authors, we must do so with those who have studied
DI in the interpretation of BP screenings. This issue
has been assessed in a preventive programme by two
working groups. The first was conducted in the
general population (4) and the second was restricted
to the obese population (5). These studies found a
proportion of DI of 32.5% and 70.2%, respectively
(4,5). Our magnitude is far below the values
obtained by these authors, although we must bear in
mind that we were working with three or more BP
readings and these authors only analysed the inter-
pretation of one altered screening test. Thus, we can-
not compare the results, as the clinical environments
and methodologies differ. This same reasoning can
be extrapolated to the factors associated with DI, in
which the other authors found an increased cardio-
vascular risk associated with this problem, whereas
we only coincide with this aspect in that older age is
associated with an increased likelihood of DI. Finally,
it was very satisfying to find that most patients who
experienced DI had BP values in the Stage I hyper-
tension category (92.8%) (12,13). This was much
lower in dyslipidemia with DI in the interpretation
of diagnostic screenings (52.3%) (7). This suggests
that in the diagnosis of hypertension, the primary
care physician is more aware of the elevated BP val-
ues when diagnosing a patient. Furthermore, in
patients with DI, when we analysed the differences
between the highest BP values and the rest, it was
notable that the prevalence of most cardiovascular
risk factors was similar, except for age and dyslipi-
demia. In other words, this appears to indicate that
the healthcare professional takes into account the BP
values themselves rather than the cardiovascular risk
factors. Fortunately, the very high BP values in the
patients experiencing DI were present in only one
out of fourteen patients.
Table 1 Analysis of patients who experienced diagnostic inertia for hypertension in a Spanish region, 2010 data
Variable
Total
n = 48,605
n (%)
Inertia
n = 6450
n (%)
Adj. OR for inertia
(95% CI) p
Male gender 11,152 (22.9) 3348 (51.7) 1.46 (1.37–1.55) < 0.001
Atrial fibrillation 427 (0.9) 102 (1.6) 0.73 (0.58–0.92) 0.007
ESCARVAL training 6422 (13.2) 729 (11.3) 0.88 (0.81–0.96) 0.005
Diabetes 8928 (18.4) 2243 (34.7) 0.93 (0.87–0.99) 0.016
Dyslipidemia 12,046 (24.8) 2818 (43.5) 0.99 (0.93–1.05) 0.637
Cardiovascular disease 1336 (2.7) 317 (4.9) 0.77 (0.67–0.88) < 0.001
Age (years)
18–44 27,090 (55.7) 529 (8.2) 1 < 0.001
45–59 5520 (11.4) 1197 (18.5) 12.45 (11.11–13.94)
60–74 9377 (19.3) 2683 (41.5) 18.11 (16.30–20.12)
≥ 75 6618 (13.6) 2041 (31.5) 20.43 (18.34–22.75)
OR were adjusted for gender, atrial fibrillation, ESCARVAL training, diabetes, dyslipidemia, cardiovascular disease and age. Goodness-
of-fit of the model: v2 = 7845.84, p < 0.001. Area under the ROC curve: 0.81. n (%), absolute frequency (relative frequency or
percentage); Adj. OR, adjusted odds ratio; CI, confidence interval.
Figure 1 ROC curve for the multivariate logistic regression
model. AUC, area under the ROC curve; CI, confidence
interval
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Implications for research and practice
This work further strengthens the concept of DI, in
which a distinction is created between inertia in the
interpretation of screening and inertia in confirming
a diagnosis. In other words, DI encompasses these
two concepts, which must be assessed separately, and
we must be cautious in their interpretation.
Lines of research are opening up that will help us
determine the causes of this inertia. All previous
publications have suggested that qualitative studies
can help to reduce this proportion and provide a
good basis for designing training programmes for
primary care physicians to update their knowledge in
cardiovascular disease (5–7,14). We believe this
would be a good line of investigation by which we
could reduce DI, achieving improved control of
hypertension in our community, and therefore a pos-
sible decrease in the incidence of cardiovascular dis-
eases. In the future, it would be interesting to
determine the outcomes of these patients suffering
DI, especially in those with BP values > 160/
100 mmHg.
Conclusion
This study helped us differentiate between DI when
interpreting an altered screening test and when fail-
ing to diagnose hypertension when there were an
adequate number of readings to do so. DI encom-
passes these two concepts. The results of three BP
measurements were used for the diagnosis of hyper-
tension, obtaining a much lower rate of DI than that
found with the interpretation of one screening test (a
single BP reading). Moreover, associated factors that
provide a preliminarily understanding of the possible
causes of this inertia were identified.
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Table 2 Analysis by BP groups of patients who experienced diagnostic inertia in a Spanish region, 2010 data
Variable
BP < 160/100 mmHg
n = 5983
n (%)
BP ≥ 160/100 mmHg
n = 467
n (%) p
Male gender 2866 (47.9) 237 (50.7) 0.236
Atrial fibrillation 95 (1.6) 7 (1.5) 0.882
ESCARVAL training 682 (11.4) 42 (9.0) 0.113
Diabetes 2086 (34.9) 156 (33.4) 0.523
Dyslipidemia 2647 (44.2) 171 (36.6) < 0.001
Cardiovascular disease 298 (5.0) 19 (4.1) 0.380
Age (years)
18–44 496 (8.3) 33 (7.1) 0.014
45–59 1121 (18.7) 76 (16.3)
60–74 2504 (41.9) 179 (38.3)
≥ 75 1862 (31.1) 179 (38.3)
p-values were obtained using the v2 test. BP, blood pressure; n (%), absolute frequency (relative frequency or percentage).
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